| hsa04979 |
Cholesterol metabolism |
50/8011 |
0.0002 |
LPL/SORT1/ABCA1/SCAR1
|
4 |
| hsa04066 |
HIF-1 signaling pathway |
109/8011 |
0.000 |
EGLN3/SLC2A1/FLT1/EGFR/PFKFB3
|
5 |
| hsa04510 |
Focal adhesion |
199/8011 |
0.001 |
KDR/VAV3/ITGB6/FLT1/TNC/EGFR
|
6 |
| hsa04015 |
Rap1 signaling pathway |
210/8011 |
0.002 |
PFN2/KDR/VAV3/FLT1/SIPA1L2/EGFR
|
6 |
| hsa05160 |
Hepatitis C |
155/8011 |
0.003 |
BID/OAS2/CLDN8/EGFR/SCARB1
|
5 |
| hsa04976 |
Bile secretion |
72/8011 |
0.011 |
SLC2A1/HMGCR/SCARB1
|
3 |
| hsa04810 |
Regulation of actin cytoskeleton |
213/8011 |
0.011 |
IQGAP2/PFN2/VAV3/ITGB6/EGFR
|
5 |
| hsa00630 |
Glyoxylate and dicarboxylate metabolism |
30/8011 |
0.016 |
SHMT2/PCCA
|
2 |
| hsa04512 |
ECM-receptor interaction |
88/8011 |
0.019 |
ITGB6/NPNT/TNC
|
3 |
| hsa05165 |
Human papillomavirus infection |
330/8011 |
0.019 |
ITGB6/TNC/HES4/ATP6V0A4/MPP5/EGFR
|
6 |
| hsa04975 |
Fat digestion and absorption |
41/8011 |
0.028 |
ABCA1/SCARB1
|
2 |
| hsa05219 |
Bladder cancer |
41/8011 |
0.028 |
MMP9/EGFR 2
|
2 |
| hsa04922 |
Glucagon signaling pathway |
106/8011 |
0.031 |
PPARGC1A/SLC2A1/PHKA2
|
3 |
| hsa04928 |
Parathyroid hormone synthesis |
106/8011 |
0.031 |
NR4A2/GATA3/EGFR
|
3 |
| hsa04670 |
Leukocyte transendothelial migration |
112/8011 |
0.035 |
VAV3/MMP9/CLDN8
|
3 |
| hsa00280 |
Valine, leucine and isoleucine degradation |
48/8011 |
0.038 |
OXCT1/PCCA
|
2 |
| hsa00510 |
N-Glycan biosynthesis |
50/8011 |
0.041 |
ST6GAL1/MGAT3
|
2 |
| hsa05110 |
Vibrio cholerae infection |
50/8011 |
0.041 |
KCNQ1/ATP6V0A4
|
2 |
| hsa04152 |
AMPK signaling pathway |
120/8011 |
0.042 |
PPARGC1A/HMGCR/PFKFB3
|
3 |
| hsa05205 |
Proteoglycans in cancer |
204/8011 |
0.042 |
KDR/VAV3/MMP9/EGFR
|
4 |
